mayo clinic glp-1 drops Beyond Ozempic: The boom Mayo Clinic researchers have developed

We examine the compelling evidence supporting GLP-1 receptor agonists (GLP-1RAs) in managing type 2 diabetes (T2D), obesity, and other diseases

[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Eisenhofer G., neman A., Friberg P., Hooper D., Fndriks L., Lonroth H., Mezey E

Our recent study demonstrated that pancreatic -cells-secreted (intraislet) GLP-1 effectively promotes maternal insulin secretion and metabolic adaptation during pregnancy

In addition, the limitations of GLP-1R agonist therapy, which may cause gastrointestinal adverse effects and significantly alter the patients physiological state, make it not widely applicable to all patients

Meanwhile, startups championing prebiotic fibre and gut health stand to gain from this shift, and giants like Nestl, Danone and Unilever all pivoting their offerings to cater to the Ozempic era

F.NagyL